Intrinsiqq
⚠ Showing the latest available close (Oct 19, 2026, 3 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.
Hartford Great Health Corp logoHartford Great Health CorpHFUS
$2.00+0.00%
Hartford Great Health Corp logo

Hartford Great Health Corp

HFUS

$2.00

+$0.00 (+0.00%)

⊜ Compare
ProfitabilityStrong marginsGrowthAcceleratingCash FlowN/AValuationRichly valued
What stands out

Margins and capital returns are both well above average: 60.20% operating margin, ROIC at 675.35%. Consistent with durable pricing power, though that alone doesn't make it a buy.

What's changing

Revenue grew 45.4%, still solid. Margins contracted 18.1pp, which offsets some of the top-line progress.

What deserves caution

At 50x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 102% versus the prior year, cash generation momentum has weakened.

Valuation context

50.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.

Price History

-11.5%

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$50M
EPS$0.04
P/E50.00
P/FCF-105.00
EV/EBITDA30.36
FCF Yield—
Div. Yield—
Net Debt/FCF0.3x
52-Week Range
$2.00$5.36

Profitability & Returns

Revenue (FY)

$2M

▲ +45.4% YoY

Net Income (TTM)

$1M

▲ +0.6% YoY

Op. Margin

60.20%

▼ -18.1pp YoY

ROIC

278.19%

▼ -29243.5pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$477K

▼ -101.6% YoY

Op. Cash Flow (TTM)

-$477K

▼ -101.5% YoY

Net Debt

-$160K

Net Cash Position

Cash & Equiv.

$160K

5Y CAGR: +105.0%

Continue Research

SourceComputed from the 10-Q filed 12 Jun 2026, covering the period ending 30 Apr 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Price from market data, last close as of 19 Oct 2026. Fiscal year ends Jul. Sector medians are approximate S&P 500 benchmarks and update periodically.

Is Hartford Great Health (HFUS) overvalued?

At a P/E of 50.0, Hartford Great Health (HFUS)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.

On quality, Hartford Great Health scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.

Frequently asked

Is Hartford Great Health a high-quality business?+

Hartford Great Health scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 60.2% operating margin and a 278.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Is Hartford Great Health a good stock to buy right now?+

That depends on valuation and quality together, not either alone. you should weigh HFUS's valuation and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.

Related stocks: Services-Computer Processing & Data Preparation

Spot a number that looks wrong? Check it in HFUS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HFUS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.